Assessment of MYC/PTEN Status by Gene-Protein Assay in Grade Group 2 Prostate Biopsies

[1]  S. Shariat,et al.  The Prognostic Impact of Intraductal Carcinoma of the Prostate: A Systematic Review and Meta-Analysis. , 2020, The Journal of urology.

[2]  H. G. van der Poel,et al.  Cribriform architecture in radical prostatectomies predicts oncological outcome in Gleason score 8 prostate cancer patients , 2020, Modern Pathology.

[3]  Ximing J. Yang,et al.  The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. , 2020, Archives of pathology & laboratory medicine.

[4]  P. Carroll,et al.  Expansile cribriform Gleason pattern 4 has histopathologic and molecular features of aggressiveness and greater risk of biochemical failure compared to glomerulation Gleason pattern 4 , 2020, The Prostate.

[5]  M. Rubin,et al.  Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer , 2020, The American journal of surgical pathology.

[6]  T. H. van der Kwast,et al.  Improved Prostate Cancer Biopsy Grading by Incorporation of Invasive Cribriform and Intraductal Carcinoma in the 2014 Grade Groups. , 2020, European urology.

[7]  A. Tewari,et al.  An updated approach to incremental nerve sparing for robot‐assisted radical prostatectomy , 2019, BJU international.

[8]  J. McKenney,et al.  Impact of Cribriform Pattern and Intraductal Carcinoma on Gleason 7 Prostate Cancer Treated with External Beam Radiotherapy. , 2019, The Journal of urology.

[9]  K. Macura,et al.  Clinical, Pathological and Oncologic Findings of Radical Prostatectomy with Extraprostatic Extension Diagnosed on Preoperative Prostate Biopsy , 2019, The Journal of urology.

[10]  M. Cooperberg,et al.  Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy. , 2018, European urology.

[11]  Esther I Verhoef,et al.  Large cribriform growth pattern identifies ISUP grade 2 prostate cancer at high risk for recurrence and metastasis , 2018, Modern Pathology.

[12]  John T. Wei,et al.  Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer , 2018, Medical Oncology.

[13]  T. H. van der Kwast,et al.  Characteristics and outcome of prostate cancer patients with overall biopsy Gleason score 3 + 4 = 7 and highest Gleason score 3 + 4 = 7 or > 3 + 4 = 7 , 2018, Histopathology.

[14]  H. Scher,et al.  Clinical implications of PTEN loss in prostate cancer , 2018, Nature Reviews Urology.

[15]  Ronald C. Chen,et al.  Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options , 2017, The Journal of urology.

[16]  M. Cooperberg,et al.  Cost‐effectiveness of the Decipher Genomic Classifier to Guide Individualized Decisions for Early Radiation Therapy After Prostatectomy for Prostate Cancer , 2017, Clinical genitourinary cancer.

[17]  D. Nieboer,et al.  Presence of invasive cribriform or intraductal growth at biopsy outperforms percentage grade 4 in predicting outcome of Gleason score 3+4=7 prostate cancer , 2017, Modern Pathology.

[18]  J. Hicks,et al.  PTEN Loss in Gleason Score 3 + 4 = 7 Prostate Biopsies is Associated with Nonorgan Confined Disease at Radical Prostatectomy , 2017, The Journal of urology.

[19]  Liying Zhang,et al.  Active Surveillance for Intermediate Risk Prostate Cancer: Survival Outcomes in the Sunnybrook Experience. , 2016, The Journal of urology.

[20]  Ziding Feng,et al.  Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort , 2016, The American journal of surgical pathology.

[21]  J Alfred Witjes,et al.  Accuracy of Magnetic Resonance Imaging for Local Staging of Prostate Cancer: A Diagnostic Meta-analysis. , 2016, European urology.

[22]  Esther I Verhoef,et al.  Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy , 2016, Modern Pathology.

[23]  P. Carroll,et al.  PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer. , 2016, European urology focus.

[24]  P. Carroll,et al.  Analytic Validation of a Clinical-Grade PTEN Immunohistochemistry Assay in Prostate Cancer by Comparison to PTEN FISH , 2016, Modern Pathology.

[25]  A. D'Amico,et al.  Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer , 2015, Prostate Cancer and Prostatic Disease.

[26]  B. Trock,et al.  PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for Active Surveillance , 2016, Modern Pathology.

[27]  Naoto Sassa,et al.  The presence of intraductal carcinoma of the prostate in needle biopsy is a significant prognostic factor for prostate cancer patients with distant metastasis at initial presentation , 2016, Modern Pathology.

[28]  Jennifer R. Rider,et al.  A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer. , 2015, Journal of the National Cancer Institute.

[29]  C. Morash,et al.  Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy , 2015, Virchows Archiv.

[30]  T. H. van der Kwast,et al.  Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort. , 2014, European journal of cancer.

[31]  O. Cussenot,et al.  8q24 amplification is associated with Myc expression and prostate cancer progression and is an independent predictor of recurrence after radical prostatectomy. , 2013, Human pathology.

[32]  T. H. van der Kwast,et al.  Copy number alterations of c‐MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy , 2012, Cancer.

[33]  Brian D. Kelly,et al.  A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections , 2012, Diagnostic Pathology.

[34]  U. Capitanio,et al.  Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. , 2012, European urology.

[35]  B. Trock,et al.  Should Intervening Benign Tissue Be Included in the Measurement of Discontinuous Foci of Cancer on Prostate Needle Biopsy? Correlation With Radical Prostatectomy Findings , 2011, The American journal of surgical pathology.

[36]  Jianfeng Xu,et al.  PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients , 2011, Clinical Cancer Research.

[37]  Wei Huang,et al.  Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome. , 2011, American journal of clinical pathology.

[38]  J. Squire,et al.  PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer , 2011, BJU international.

[39]  L. Rimsza,et al.  Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma , 2010, Haematologica.

[40]  W. Gerald,et al.  Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer , 2010, British Journal of Cancer.

[41]  Yu Cheng,et al.  Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. , 2007, Journal of the National Cancer Institute.

[42]  J. Squire,et al.  FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome , 2007, British Journal of Cancer.

[43]  R. Lothe,et al.  8q Gain Is an Independent Predictor of Poor Survival in Diagnostic Needle Biopsies from Prostate Cancer Suspects , 2006, Clinical Cancer Research.

[44]  L. Egevad,et al.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma , 2005, The American journal of surgical pathology.